95 related articles for article (PubMed ID: 2552665)
1. Identification of an enhancer-type sequence that is responsive to Z and R trans-activators of Epstein-Barr virus.
Shimizu N; Sakuma S; Ono Y; Takada K
Virology; 1989 Oct; 172(2):655-8. PubMed ID: 2552665
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence.
Shimizu N; Takada K
J Virol; 1993 Jun; 67(6):3240-5. PubMed ID: 8388498
[TBL] [Abstract][Full Text] [Related]
3. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.
Holley-Guthrie EA; Quinlivan EB; Mar EC; Kenney S
J Virol; 1990 Aug; 64(8):3753-9. PubMed ID: 2164595
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a bovine herpesvirus 4(BHV-4) 1.1-kb RNA and its transactivation by BHV-4 immediate-early 2 gene product.
Bermudez-Cruz R; Zhang L; van Santen VL
Arch Virol; 1998; 143(12):2391-412. PubMed ID: 9930195
[TBL] [Abstract][Full Text] [Related]
5. The Epstein-Barr virus (EBV) ORI1yt enhancer is not B-cell specific and does not respond synergistically to the EBV transcription factors R and Z.
Gruffat H; Moreno N; Sergeant A
J Virol; 1990 Jun; 64(6):2810-8. PubMed ID: 2159545
[TBL] [Abstract][Full Text] [Related]
6. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.
Kenney S; Holley-Guthrie E; Mar EC; Smith M
J Virol; 1989 Sep; 63(9):3878-83. PubMed ID: 2548003
[TBL] [Abstract][Full Text] [Related]
7. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Adamson AL; Kenney SC
Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
[TBL] [Abstract][Full Text] [Related]
8. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor.
Zalani S; Holley-Guthrie EA; Gutsch DE; Kenney SC
J Virol; 1992 Dec; 66(12):7282-92. PubMed ID: 1331521
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection.
Sista ND; Pagano JS; Liao W; Kenney S
Proc Natl Acad Sci U S A; 1993 May; 90(9):3894-8. PubMed ID: 8387200
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.
Le Roux F; Sergeant A; Corbo L
J Gen Virol; 1996 Mar; 77 ( Pt 3)():501-9. PubMed ID: 8601788
[TBL] [Abstract][Full Text] [Related]
11. Identification of the 12-O-tetradecanoylphorbol-13-acetate-responsive enhancer of the MS gene of the Epstein-Barr virus.
Liu Q; Summers WC
J Biol Chem; 1992 Jun; 267(17):12049-54. PubMed ID: 1318308
[TBL] [Abstract][Full Text] [Related]
12. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.
Quinlivan EB; Holley-Guthrie EA; Norris M; Gutsch D; Bachenheimer SL; Kenney SC
Nucleic Acids Res; 1993 Jul; 21(14):1999-2007. PubMed ID: 8393562
[TBL] [Abstract][Full Text] [Related]
13. The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.
Buisson M; Manet E; Trescol-Biemont MC; Gruffat H; Durand B; Sergeant A
J Virol; 1989 Dec; 63(12):5276-84. PubMed ID: 2555554
[TBL] [Abstract][Full Text] [Related]
14. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.
Cox MA; Leahy J; Hardwick JM
J Virol; 1990 Jan; 64(1):313-21. PubMed ID: 2152819
[TBL] [Abstract][Full Text] [Related]
15. Negative regulation of the BZLF1 promoter of Epstein-Barr virus.
Montalvo EA; Shi Y; Shenk TE; Levine AJ
J Virol; 1991 Jul; 65(7):3647-55. PubMed ID: 1645787
[TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
17. The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R.
Chevallier-Greco A; Gruffat H; Manet E; Calender A; Sergeant A
J Virol; 1989 Feb; 63(2):615-23. PubMed ID: 2536097
[TBL] [Abstract][Full Text] [Related]
18. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.
Rooney C; Taylor N; Countryman J; Jenson H; Kolman J; Miller G
Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9801-5. PubMed ID: 2849118
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
[TBL] [Abstract][Full Text] [Related]
20. The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.
Chen H; Lee JM; Wang Y; Huang DP; Ambinder RF; Hayward SD
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):9339-44. PubMed ID: 10430944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
